Neph.Ns

NephroPlus maintains a strong liquidity position with a current ratio of 2.01, indicating that its current assets significantly exceed its current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. Operating cash flow stands at INR 78.24 million, but free cash flow is negative at INR 237.05 million, primarily due to capital expenditures of INR 298.04 million.

Profitability metrics show a return on equity of 6.8% and a return on assets of 5.33%. These figures are below the industry median for healthcare facilities and services, indicating that NephroPlus is underperforming in terms of asset and equity utilization compared to its peers. The company's net income of INR 36.39 million is modest relative to its revenue of INR 460.31 million, with a net margin of 7.9%.

Geographically, NephroPlus is concentrated in India, with no disclosed international operations. Revenue is derived from outpatient and inpatient dialysis services, with no material diversification across business segments. The company's revenue concentration in a single country and service line increases exposure to local economic and regulatory risks.

Looking ahead, NephroPlus is expected to see a modest increase in revenue, with a projected growth rate of 4.5% for the current fiscal year and 5.2% for the next fiscal year. This growth is driven by expansion in dialysis centers and increased patient volume. However, the company's capital expenditures remain high, which may constrain free cash flow unless operating cash flow improves.

Risk factors for NephroPlus include liquidity risk due to negative free cash flow and high capital expenditures. The company has no immediate dilution risk, as shares outstanding remain unchanged between basic and diluted measures. However, the absence of long-term debt does not eliminate the need for ongoing capital investment, which could lead to future financing needs.

Recent events include the filing of the latest annual report, which disclosed continued investment in new dialysis centers and a focus on expanding patient access. No material regulatory or legal issues were reported in the latest filings, and the company remains in compliance with healthcare regulations in India.